Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.56 |
| ▸ | MMP13 | P45452 | 4/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 4/20 | 0.40 |
| ▸ | MMP10 | P09238 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165406 | 0.88 | P2RX7 (0.47) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10162782 | 0.86 | P2RX7 (0.47) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10162831 | 0.86 | MMP13 (0.47) | P2RX7MMP13 | |
| SCHEMBL10168167 | 0.84 | P2RX7 (0.44) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10162789 | 0.84 | P2RX7 (0.44) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10168157 | 0.83 | P2RX7 (0.43) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10168153 | 0.83 | VNN1 (0.50) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL13593907 | 0.82 | P2RX7 (0.43) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10209881 | 0.82 | P2RX7 (0.45) | P2RX7MMP13RPS6KB1PTPN7DUSP3 | |
| SCHEMBL10168330 | 0.78 | P2RX7 (0.39) | P2RX7MMP13RPS6KB1PTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | P2RX7 3795/4885MMP13 1/4885RPS6KB1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.